Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event
- PMID: 33689217
- PMCID: PMC8120411
- DOI: 10.1002/ehf2.13155
Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event
Abstract
Aims: The aim of this study is to characterize healthcare resource utilization and costs in patients with heart failure with reduced ejection fraction (HFrEF) following a worsening heart failure event.
Methods and results: This was a retrospective observational cohort analysis. Patients with HFrEF were identified from the PINNACLE Registry and linked to a nationwide pharmacy and medical claims database. Worsening heart failure was defined as stable heart failure with a subsequent hospitalization and/or intravenous diuretic therapy. Healthcare resource use and costs in 2015 US dollars were analysed for dispensed prescriptions, outpatient encounters, and hospital encounters. Among 11 064 patients with HFrEF, 3087 (27.9%) experienced a worsening heart failure event during an average follow-up of 973 days. During the first 30 days after the worsening event, 19.8% of patients had hospital readmissions with heart failure as the primary or secondary diagnosis. During that same time period, mean per patient heart failure-related healthcare resource use included 1.3 prescriptions, 0.5 practitioner visits, and 0.5 hospital encounters (admissions, observations, or emergency care), for an average total medical cost of $8779 per patient including $5359 in heart failure-related costs. During the first year following worsening heart failure onset, mean per patient total and heart failure-related costs were $62 615 and $35 329, respectively.
Conclusions: The economic burden following a worsening heart failure event calls for further review of methods to prevent progressive disease, improve adherence to guideline-directed therapy, and develop novel treatments and care strategies to moderate further progression.
Keywords: Cost and cost analysis/economics; Health resources; Heart failure/complications; Hospitalization.
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Conflict of interest statement
M. Givertz has research support from the National Institutes of Health and serves as a consultant to Merck. J. Butler has received research support from the National Institutes of Health, PCORI, and the European Union and serves as a consultant for Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squib, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, StealthPeptide, SC Pharma, Vifor, and ZS Pharma. G. Hess was previously employed by Symphony Health, which received research support from Merck & Co. for the design and conduct of this study. G. Hess also conducts funded studies with governmental agencies, for example, the NIH, and professional societies, for example, the American College of Cardiology. M. Yang and B. Zhao are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., and are shareholders of Merck & Co., Inc., Kenilworth, NJ, USA.
Figures



References
-
- Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG, American Heart Association Advocacy Coordinating Committee , Council on Arteriosclerosis, Thrombosis and Vascular Biology , Council on Cardiovascular Radiology and Intervention , Council on Clinical Cardiology , Council on Epidemiology and Prevention , Stroke Council . Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013; 6: 606–619. - PMC - PubMed
-
- Hall MJ, Levant S, DeFrances CJ. Hospitalization for congestive heart failure: United States, 2000–2010. NCHS Data Brief 2012: 1–8. - PubMed
-
- Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. Pharmacoeconomics 2008; 26: 447–462. - PubMed
-
- Setoguchi S, Stevenson LW. Hospitalizations in patients with heart failure: who and why. J Am Coll Cardiol 2009; 54: 1703–1705. - PubMed
-
- Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007; 154: 260–266. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical